[Form 4] Immix Biopharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Immix Biopharma, Inc. (IMMX) – Form 4 insider filing dated 06/23/2025

Director Jane Buchan reported one equity award and updated share ownership as of 06/20/2025:

• New derivative grant: 33,000 non-qualified stock options with an exercise price of $2.24 per share, expiring 06/20/2035. The options vest in 12 equal monthly installments beginning on the grant date, contingent on continued service (Note 1).
• Post-transaction ownership: 22,455 shares of common stock held directly. No common shares were bought or sold in the reported period; the table only updates the total beneficial ownership.

No cash consideration was paid for the option grant (price listed as $0.00), indicating a routine director compensation award. The filing does not disclose any simultaneous open-market transactions, earnings data, or major corporate events.

Investors should note that while option grants can create future dilution if exercised, the 33,000-share award is relatively small and vests over one year, spreading potential dilution. The filing aligns the director’s incentives with shareholder value but, by itself, does not signal immediate changes to Immix Biopharma’s financial outlook.

Positive

• Equity-based compensation aligns director incentives with shareholder value through a 33,000-option grant.
• Timely filing and compliance reinforce sound corporate governance practices.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine director option grant; minimal dilution; neutral impact.

The 33,000-share option grant at $2.24 is standard board compensation. It vests monthly over a year, indicating service-based incentives rather than performance triggers. With only 22,455 shares currently owned, total potential ownership if fully exercised would rise to 55,455 shares, still an immaterial percentage of Immix’s float. No common stock sale occurred, so there is no bearish signal. Given the modest size and absence of additional context, the filing is neutral for valuation and liquidity.

Corporate Governance Specialist

TL;DR: Standard Form 4 shows alignment of interest; governance practices intact.

The company continues to compensate directors primarily through equity, consistent with governance best practices encouraging long-term alignment. Monthly vesting over 12 months links retention to board service. The power-of-attorney reference and timely filing (three days post-transaction) indicate procedural compliance. There is no indication of 10b5-1 plan usage, and the filing checks the Rule 10b5-1 box unchecked, reflecting discretionary award rather than pre-planned trades. Overall, this is a routine, non-impactful disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BUCHAN JANE

(Last) (First) (Middle)

C/O IMMIX BIOPHARMA, INC.

11400 WEST OLYMPIC BLVD., SUITE 200

(Street)

LOS ANGELES CA 90064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								22,455	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.24	06/20/2025		A		33,000		(1)	06/20/2035	Common Stock	33,000	$0.00	33,000	D

Explanation of Responses:

1. The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.

Remarks:

See Power of Attorney filed as Exhibit 24.1 to the Form 3 filed by the Reporting Person on December 15, 2021.

	/s/ Ilya Rachman as Attorney-In-Fact for Jane Buchan	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Immix Biopharma (IMMX) stock options were granted to Director Jane Buchan?

The Form 4 reports a grant of 33,000 stock options exercisable at $2.24 per share.

What is the exercise price and expiration date of the new options for IMMX?

The options carry a $2.24 exercise price and expire on 06/20/2035.

Did Jane Buchan buy or sell any IMMX common shares in this filing?

No common shares were bought or sold; only total ownership of 22,455 shares was reported.

When will the newly granted IMMX options vest?

They vest in 12 equal monthly installments following the 06/20/2025 grant date, subject to continued service.

Does the filing indicate use of a Rule 10b5-1 trading plan?

The checkbox for Rule 10b5-1(c) was left unchecked, so the transaction was not made under a pre-arranged trading plan.